SCHEMBL711902

SCHEMBL711902

C1CCC(CNCC2C3CN(CC4CC4)CC23)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 2/20 0.42
ADRA2C P18825 1/20 0.42
GBA1 P04062 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
ACHE P22303 1/20 0.38
SCN1A P35498 1/20 0.37
SCN4A P35499 1/20 0.37
SCN7A Q01118 1/20 0.37
KCNH2 Q12809 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN9A Q15858 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
SCN11A Q9UI33 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
ADH1B P00325 1/20 0.36
ADH1C P00326 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL711161 0.83 HSD11B1 (0.36) ACHEADH1BADH1CADH1AADH4
SCHEMBL708363 0.79 ADH1B (0.38) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL711123 0.76 KDM4E (0.34) ADH1BADH1CADH1AADH4ADH7
SCHEMBL711901 0.74 EPHX1 (0.51) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL1678148 0.74 ADH1B (0.56) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL1678338 0.74 ADH1B (0.56) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL1679343 0.74 ADH1B (0.56) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL5507916 0.73 CXCR4 (0.46) CXCR4SMN1; SMN2
SCHEMBL1679033 0.72 ADH1B (0.59) CHRM5ADRA2CCHRM2CHRM4CHRM1
SCHEMBL1679102 0.72 ADH1B (0.59) CHRM5ADRA2CCHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 CHRM5 547/4885ADRA2C 795/4885GBA1 192/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 CHRM5 574/4885ADRA2C 682/4885GBA1 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.